brain health – Ayurved Healing

Jatamansi for Neurodegenerative Disease: What Neuroprotection Research Shows

Dr. Meera Iyer — Fri, 08 May 2026 09:00:00 +0000

The human brain consumes approximately 20% of the body’s total oxygen supply while accounting for only 2% of body weight. This metabolic intensity makes neurons extraordinarily vulnerable to oxidative stress, mitochondrial dysfunction, and the misfolded protein aggregates that define neurodegenerative disease. Alzheimer’s disease pathology, characterized by amyloid-beta plaques and neurofibrillary tau tangles, develops over decades before clinical symptoms emerge. Parkinson’s disease involves progressive loss of dopaminergic neurons in the substantia nigra that begins years before the characteristic tremor appears. The window for meaningful neuroprotective intervention is early, and conventional pharmacological options remain limited.

In this landscape, Jatamansi (Nardostachys jatamansi, also known as Spikenard) has a long pedigree in Ayurvedic neurology. The classical nighantus (materia medica) and major compendia describe it as a medhya (intellect-supporting) and nervine dravya valued for disorders of the mind and nervous system. An important correction is warranted at the outset, because it is often misstated: Jatamansi is not one of the four Medhya Rasayana herbs that Charaka names in the Rasayana section of the Chikitsa Sthana. Charaka’s four primary Medhya Rasayanas are Mandukaparni (Centella asiatica), Yashtimadhu (Glycyrrhiza glabra), Guduchi (Tinospora cordifolia) and Shankhapushpi (Convolvulus pluricaulis), with Shankhapushpi singled out as foremost; some regional lineages substitute Brahmi and Vacha. Jatamansi belongs instead to the broader family of medhya and sleep-promoting (nidrajanana) nervines that classical practice deploys for unmada (psychosis), apasmara (seizure disorders) and anidra (insomnia).

Classical Ayurvedic Understanding

Jatamansi is catalogued in the Karpuradi Varga of the Bhavaprakasha Nighantu. Its rasa panchaka (pharmacological profile) is described as tikta (bitter), kashaya (astringent) and madhura (sweet) in rasa; laghu (light) and snigdha (unctuous) in guna; sheeta (cooling) in virya; and katu (pungent) in vipaka. It is regarded as tridoshahara — pacifying all three doshas — with a particular affinity for aggravated vata and pitta. Classical authors attribute to it medhya, hridya (cardiotonic) and varnya (complexion-improving) actions, alongside its well-known calming, sleep-promoting effect on the mind. This cooling, grounding, vata-and-pitta-settling character is precisely why traditional physicians reach for it in agitated, sleepless and disordered mental states rather than as a stimulant tonic.

Active Compounds and Their Chemistry

Jatamansi root carries a complex phytochemical profile in which the sesquiterpenes are most closely associated with its central nervous system effects. The following constituents are the best characterised:

Jatamansone (valeranone): The principal sesquiterpene ketone, identified in the mid-twentieth century. It is the constituent most often linked to the herb’s sedative, calming action in animal models.
Spirojatamol: A structurally distinct sesquiterpene alcohol. It is a separate molecule from jatamansone and should not be treated as a synonym for it, as is sometimes done in error.
Nardosinone and related sesquiterpenoids (nardostachone, nardol): Characteristic sesquiterpenoids of the genus carrying ketone and alcohol functionalities; they are not “sesquiterpene acids.”
Coumarins (jatamansin, jatamansinol): Coumarin-type constituents that contribute antioxidant activity.
Actinidine: An iridoid-derived alkaloid, also reported in the related Valerian group, with central activity.

The lipophilic nature of most Jatamansi sesquiterpenes is consistent with their traditional centrally acting use, since lipophilic small molecules cross the blood-brain barrier more readily — a pharmacokinetic feature that many synthetic neuroprotective candidates have struggled to satisfy.

Traditional Neurological and Psychiatric Applications

Across the classical literature Jatamansi is a manas (mind) herb. It appears in formulations directed at unmada (psychotic and mood disturbance), apasmara (epileptic and seizure disorders), anidra (insomnia) and smritibhramsha (memory disturbance), and is used both internally and as a medicated oil. Classical and traditional preparations that feature Jatamansi include the Mamsyadi group of decoctions (Mamsyadi Kwatha, in which “Mamsi” denotes Jatamansi) used for disordered mental states, and the compound psychiatric formulation Manasamitra Vataka. Externally, Jatamansi taila is applied in shiroabhyanga (head massage) and pada-abhyanga (foot massage) for its calming, sleep-supporting effect. These applications represent the verified, text-based foundation of the herb’s reputation, independent of any modern claim.

Alzheimer’s Disease: Ayurvedic Correlation and Research Status

From an Ayurvedic standpoint, the progressive cognitive decline of Alzheimer’s disease is most often correlated with derangement of vata and of majja dhatu, expressed as smritibhramsha and buddhi-vibhramsha (loss of memory and discernment). On this reasoning a cooling, vata-settling medhya nervine such as Jatamansi is a logical adjunct within a broader Rasayana strategy rather than a standalone cure. On the modern side, the honest position is that preclinical work has explored antioxidant and general neuroprotective activity for Nardostachys extracts, but rigorous, reproducible human evidence specific to Alzheimer’s disease does not exist.

Parkinson’s Disease: Ayurvedic Correlation and Research Status

Parkinson’s disease is correlated in modern Ayurvedic practice with Kampavata, a vata-predominant disorder marked by kampa (tremor) and stiffness, and management is built around vata-pacifying, nervine and Rasayana measures. Jatamansi is used supportively within such regimens for its calming and nervine qualities. Jatamansi has a long traditional record in vata-type neurological complaints, and any monoaminergic effect remains, at best, preliminary and unconfirmed.

Oxidative Stress and Neuroinflammation

Both Alzheimer’s and Parkinson’s disease share oxidative stress and microglial-driven neuroinflammation as core processes, and this is the mechanistic space in which a traditionally antioxidant nervine would plausibly act. Preclinical studies of Nardostachys extracts have, in general terms, reported antioxidant activity, which is consistent with the cooling, pitta-and-vata-settling description in classical sources. The defensible summary is that an antioxidant, calming profile is biologically plausible and traditionally supported, while precise anti-inflammatory potency in humans is not established.

Clinical Evidence and Limitations

The candid picture is that Jatamansi neuroprotection research remains largely preclinical and traditional. Human clinical trials specifically for neurodegenerative disease are absent, and even the better-known sedative, anxiolytic and sleep-supporting uses rest more on centuries of classical practice and small or preliminary investigations than on large, replicated randomized trials. Readers should weigh Jatamansi as a traditionally established nervine with an encouraging but still immature modern evidence base — not as a proven disease-modifying therapy.

Application	Ayurvedic Basis	Modern Evidence Level	Practical Note
Insomnia (anidra) / calming	Classical nervine, sleep-promoting use	Traditional + preliminary	Best-established traditional role
Mental agitation, unmada	Manas formulations (e.g. Mamsyadi)	Traditional	Used within compound formulae, not alone
Memory support (medhya)	Medhya/nervine dravya (not one of Charaka’s four)	Traditional + early preclinical	Adjunct to true Medhya Rasayanas
Antioxidant / neuroprotection	Cooling, vata-pitta settling profile	Preclinical (general)	Plausible; human disease data absent
Alzheimer’s / Parkinson’s disease	Correlated with vata, majja, Kampavata	No human disease trials	Supportive only; under specialist care

Dosage and Administration Protocols

The following reflect commonly used traditional dosing ranges; exact dose, vehicle (anupana) and duration should be set by a qualified Ayurvedic physician according to the individual’s constitution and condition.

Jatamansi churna (powder): 500 mg to 1 gram twice daily, traditionally with warm milk or honey. Higher amounts are used only under direct physician supervision.
Jatamansi taila (oil, external use): Applied to the scalp (shiroabhyanga) and soles of the feet (pada-abhyanga) for its calming, sleep-supporting effect.
Jatamansi with Brahmi: A combination commonly used by practitioners for manas and cognitive complaints — Brahmi (Bacopa monnieri) for cognition and Jatamansi for its calming, sleep-promoting support. This is a practical clinical pairing, not Charaka’s defined set of four Medhya Rasayanas, and should not be described as such.
Duration: Determined individually by the prescribing physician. Classical Rasayana regimens vary widely in length depending on the preparation and the person; there is no single fixed “three months on, one month off” textual rule.

Drug Interactions and Safety Considerations

Jatamansi has a centrally calming, sedative-type action, and on precautionary grounds the following interactions deserve attention even where formal human data are limited:

Sedatives and benzodiazepines: Additive CNS depression is plausible; doses may need adjustment and monitoring.
MAO inhibitors (phenelzine, tranylcypromine, selegiline, rasagiline): Any influence of Jatamansi on monoaminergic activity is preliminary and unconfirmed, but combining centrally active botanicals with MAO inhibitors warrants caution as a default safety measure.
SSRIs and SNRIs: Theoretical caution with serotonergic agents; monitor for excess effects.
Levodopa and Parkinson’s medication: Use only under specialist supervision; do not alter prescribed dopaminergic therapy.
Pregnancy and lactation: Safety data are insufficient; avoid until better evidence is available.

For how Jatamansi sits within the broader category of rejuvenative herbs, see our post on Rasayana therapy and longevity. For the companion herb Brahmi’s clinical detail, see our guide on Bacopa monnieri clinical dosage. For Kapikacchu in Parkinson’s disease, see our coverage of Kapikacchu and Parkinson’s clinical trials.

The Research Gap and Clinical Opportunity

Jatamansi presents a genuine opportunity that should be neither overstated nor dismissed. It has a centuries-long, text-documented record as a calming nervine and medhya herb, a lipophilic chemistry suited to central activity, and a traditional safety profile at customary doses. What it does not yet have is the controlled human trial evidence needed to claim disease modification in Alzheimer’s or Parkinson’s disease. The responsible framing is that the herb deserves rigorous study, not that such study has already vindicated specific molecular mechanisms. For adults with cognitive concerns or a family history of neurodegenerative disease, Jatamansi may be considered only as a low-risk adjunct within a properly supervised plan — and any use should be disclosed to the treating physician.

Safety Disclaimer: This article reviews traditional Ayurvedic knowledge and preliminary research and does not constitute medical advice for neurodegenerative disease management. Alzheimer’s and Parkinson’s diseases are serious conditions requiring specialist neurological care. Do not start, stop or modify any prescribed medication based on this article. Jatamansi has a sedative action and possible interactions with sedatives and centrally acting drugs. Always consult a qualified Ayurvedic practitioner and disclose all herbal supplements to your neurologist or primary care physician before use.

References

OCD Patterns Through Dosha Theory: Ayurvedic Support for Obsessive Thinking

Vikram Desai — Thu, 23 Apr 2026 12:00:00 +0000

Obsessive-compulsive disorder is a modern psychiatric diagnosis, and Ayurveda should be used only as a complementary support for people already working with appropriate mental-health care. The useful Ayurvedic question is not “What is the Ayurvedic name for OCD?” but “Which patterns of manas, dosha, lifestyle, and nervous-system strain are present in this person, and how can they be steadied without creating new rituals?” In that sense, Ayurveda can offer a structured way to support steadiness, sleep, digestion, daily rhythm, and emotional regulation alongside Cognitive Behavioral Therapy with Exposure and Response Prevention, medication when prescribed, and regular psychiatric follow-up.

OCD Through the Ayurvedic Lens

Ayurveda does not contain a direct diagnostic equivalent to OCD as defined in modern psychiatry. Classical texts discuss serious disturbances of mind under broad categories such as Unmada, but Unmada is not the same as OCD and should not be presented as a one-to-one match. The more accurate Ayurvedic lens is to understand obsessive thinking through manas, the three mental qualities of sattva, rajas, and tamas, and the influence of vata, pitta, and kapha on mental function.

In classical Ayurvedic language, rajas is associated with agitation, movement, and disturbance, while tamas is associated with heaviness, dullness, and obstruction. A person with obsessive thinking may show a rajasic pattern of mental speed, fear, urgency, checking, and inner restlessness; another may show a tamasic pattern of stuckness, avoidance, withdrawal, and inability to move on from a thought. The aim of Ayurvedic support is to strengthen sattva: clarity, steadiness, discernment, and the ability to pause before acting on an impulse.

The dosha picture is usually mixed rather than simple. A vata-dominant presentation may involve racing thoughts, fear, irregular sleep, sensory sensitivity, and difficulty feeling grounded. A pitta-dominant presentation may involve intensity, frustration, perfectionism, harsh self-judgment, and a driven need for exactness. A kapha-dominant presentation may involve mental heaviness, repetitive attachment to one concern, lethargy, and difficulty initiating change. Many people show more than one of these patterns, so the protocol must be individualized.

Medhya Rasayana and Nervine Herbs for Obsessive Thinking

Medhya rasayana is the Ayurvedic category of substances traditionally used to support medha, a term connected with intellect, comprehension, memory, and mental steadiness. These herbs are best understood as constitutional and nervous-system supports, not as direct replacements for psychiatric treatment. They should be selected by a qualified Ayurvedic practitioner with full knowledge of the person’s medications, sleep pattern, digestion, liver health, pregnancy status, and psychiatric history.

Herb	Verified Ayurvedic Role	Classical/API Dose Reference	Important Caution
Brahmi (Bacopa monnieri)	Described as medhya, rasayana, vatahara, kaphahara, and supportive in disturbances of mind.	API lists 1–3 g of powder as a general adult oral dose.	Supplement forms may cause digestive upset in some people. Use with supervision when taking psychiatric medication.
Shankhapushpi (Convolvulus pluricaulis)	Described as medhya, rasayana, pittahara, balya, and traditionally used in manasaroga.	API lists 3–8 g of powder as a general adult oral dose.	May be calming or sedating for some people. Use carefully with sedatives or psychiatric medicines.
Jatamansi (Nardostachys jatamansi)	Described as medhya, nidrajanana, and tridoshanut, with traditional use in manasaroga and anidra.	API lists 2–3 g powder or 5–10 g decoction as general adult oral dose references.	Because it is sleep-promoting, do not combine it with sedatives, alcohol, or psychiatric medicines without clinician oversight.
Ashwagandha (Withania somnifera)	Described as rasayana, balya, and vata-kapha-pacifying; best suited when depletion, poor resilience, and vata strain are prominent.	API lists 3–6 g of root powder as a general adult oral dose.	Its heating quality is not suitable for every pitta-dominant presentation. Use with professional guidance when taking thyroid, sedative, immune-active, or psychiatric medicines.
Guduchi (Tinospora cordifolia)	Classically included among medhya rasayana substances and used as a rasayana support when selected appropriately.	Form and dose should be individualized by a practitioner rather than self-prescribed for mental-health support.	Avoid self-directed concentrated use, especially with liver disease, autoimmune history, abnormal liver tests, or multiple medications.

The Vata-Pitta Support Protocol

The most common Ayurvedic support pattern for obsessive thinking is a mixed vata-pitta protocol: calm the speed of vata, cool the intensity of pitta, and avoid any practice that becomes another compulsion. The goal is not to create a perfect routine, but to create enough steadiness that the person can participate more effectively in therapy, sleep more regularly, and reduce avoidable triggers.

Component 1: Ground the Moving Mind

When vata is prominent, the first treatment is rhythm. Meals, sleep, waking time, and therapeutic practices should be simple, warm, and predictable. Daily abhyanga with warm oil, especially to the feet, scalp, ears, and lower legs, is a practical vata-calming method when it does not become excessive or rule-bound. Professional shirodhara, in which a steady stream of warm liquid is poured over the forehead, may be used by trained practitioners as a calming therapy, but it is not necessary for every person and should not be treated as a stand-alone cure.

Component 2: Cool the Driven Intensity

When pitta is prominent, reduce heat, intensity, and over-control in daily life. During flare-ups, many people do better with fewer stimulants, less alcohol, less very spicy or sour food, and fewer late-night work sessions. Cooling supports may include coriander, fennel, rose, coconut, adequate hydration, and time away from competitive or overstimulating environments. Meditation should be gentle and spacious; highly structured counting practices can become problematic if the person begins to use them as reassurance or neutralization rituals.

Component 3: Prevent Ayurvedic Practices from Becoming Rituals

This is the most important clinical point. A breathing practice, mantra, diet rule, oil massage, or herbal schedule can become part of the obsessive-compulsive cycle if it is used to neutralize fear or achieve certainty. Ayurvedic support should be coordinated with the person’s therapist so that it does not interfere with exposure and response prevention. The test is simple: a practice should increase flexibility, not make the person more dependent on perfect performance.

Dietary Considerations for Obsessive Patterns

Diet is supportive rather than curative. For vata-pitta obsessive patterns, the most useful dietary principle is regularity without rigidity. Warm, freshly prepared meals at consistent times are often preferable to skipping meals, grazing, fasting, or cycling between strict food rules and chaotic eating. Ghee, cooked grains, soups, stews, warm milk when tolerated, soaked almonds, mung dal, and cooked vegetables can be used when the person needs grounding and nourishment.

Caffeine, alcohol, very spicy foods, and late-night eating can aggravate some vata-pitta patterns, especially when sleep is already poor or the mind feels overheated and urgent. Fermented foods are not automatically good or bad; they may be useful for one constitution and aggravating for another. The guiding principle is to observe the individual response without turning food into a purity system. A person with OCD should not be encouraged to build an overly restrictive diet around fear, contamination, or moral perfection.

Pranayama for Obsessive Thought Reduction

Pranayama can be helpful when it is brief, flexible, and non-compulsive. Nadi Shodhana, or alternate nostril breathing, is traditionally used to steady the flow of breath and attention. Bhramari, or humming bee breath, emphasizes a long humming exhalation and is often used to settle agitation. For obsessive-compulsive patterns, both practices should be kept simple: a few relaxed rounds, no perfectionism about count, and no restarting because a breath felt “wrong.”

People who become anxious while focusing on the breath can modify pranayama by keeping the eyes open, breathing naturally, using a shorter duration, or practicing while walking slowly. Breath retention, forceful breathing, and long counted rounds are not appropriate for everyone. If breathing practice becomes a reassurance ritual, it should be paused or redesigned with guidance from a therapist and a qualified practitioner.

How Ayurveda Fits Beside ERP and Medication

Ayurveda fits best around established OCD care rather than in place of it. Exposure and Response Prevention asks the person to face feared triggers while resisting compulsive neutralization. Ayurvedic support should make that work more tolerable by improving sleep, digestion, daily rhythm, and baseline resilience. It should not promise certainty, purity, or complete control, because those promises can feed the same pattern that OCD exploits.

A practical plan may include a stable wake time, regular meals, evening oiling of the feet, one carefully chosen medhya herb, gentle pranayama, and a cooling or grounding diet matched to the person’s constitution. The plan should be written simply and reviewed often. If the person feels compelled to repeat practices, add more rules, or seek reassurance through the protocol, the plan should be simplified immediately.

Safety note: OCD is a serious mental-health condition. Cognitive Behavioral Therapy with Exposure and Response Prevention and, where appropriate, SSRI medication are established treatments. Ayurvedic herbs and therapies should be used only as complementary support and with the knowledge of the person’s psychiatrist, therapist, physician, or qualified Ayurvedic practitioner. Seek urgent medical help if symptoms are severe, rapidly worsening, associated with self-harm, or preventing basic daily functioning. Do not stop or reduce psychiatric medication without the prescribing clinician’s guidance.

Nothing in this article diagnoses or treats a medical condition. Use it as educational information and consult a qualified Ayurvedic practitioner or healthcare provider before starting herbs, supplements, detoxes, or therapeutic protocols, especially if pregnant, managing a medical or psychiatric condition, or taking medication.

Actionable tip: For one week, choose only one stabilizing experiment: either eat meals at consistent times or remove caffeine and observe sleep, anxiety, and intrusive-thought intensity. Keep the experiment simple. The goal is not perfection; the goal is to notice whether steadier daily rhythm reduces the background conditions that make obsessive thinking feel louder.

References

Shankhavali (Evolvulus alsinoides): The Memory Herb Overshadowed by Brahmi

Rohan Kapoor — Sun, 05 Apr 2026 07:30:00 +0000

Every Ayurvedic student learns Brahmi, yet the smaller blue-flowered Shankhavali tradition deserves a careful place in the conversation on memory herbs. In regional practice, Evolvulus alsinoides is known by names such as Vishnukranta, Shankhavel, and Shankhpushpi. Its identity must be handled precisely, because the official Ayurvedic Pharmacopoeia of India monograph for Shankhapushpi is Convolvulus pluricaulis, while the same monograph notes that Evolvulus alsinoides and Clitoria ternatea are used as Shankhapushpi in certain parts of India.

What Is Shankhavali?

Shankhavali, in this article, refers to the regional Shankhpushpi/Vishnukranta use of Evolvulus alsinoides, a small annual or perennial herb of the Convolvulaceae family. Kew’s Plants of the World Online accepts Evolvulus alsinoides as a valid species and describes its native range as the tropics and subtropics. Indian biodiversity sources list common names such as Vishnukranta, Shankhpushpi, Vishnu Kranthi, and Shankhavel, reflecting its wide regional use.

The plant is a slender, hairy, prostrate or ascending herb with small blue flowers that may also appear white. This botanical profile is one reason it becomes confused with other Shankhpushpi plants in commerce. For clinical and educational writing, it is best to state the botanical name clearly: Evolvulus alsinoides when discussing Shankhavali/Vishnukranta, and Convolvulus pluricaulis when discussing the official API Shankhapushpi monograph.

The Shankhpushpi Identity Problem

The name Shankhpushpi is not used for one single plant in all regions. The Ayurvedic Pharmacopoeia of India identifies Shankhapushpi as the whole plant of Convolvulus pluricaulis Choisy and gives its official pharmacopoeial standards, properties, dose, and formulations. The same monograph adds that Clitoria ternatea and Evolvulus alsinoides are used as Shankhapushpi in certain parts of India. This explains why Shankhavali is sometimes overshadowed: its reputation is real, but its name is shared with related regional substitutes and market sources.

Distinguishing Shankhavali from Brahmi

Brahmi and Shankhavali both belong to the wider Ayurvedic memory-tonic conversation, but they are not the same herb and should not be interchanged casually. Brahmi is officially represented in the API as Bacopa monnieri, while Shankhavali refers here to Evolvulus alsinoides, a regional Shankhpushpi source. Their botanical identity, pharmacological markers, and evidence profiles differ.

Feature	Shankhavali / Vishnukranta (E. alsinoides)	Brahmi (B. monnieri)
Botanical family	Convolvulaceae	API lists Bacopa monnieri as Brahmi
Ayurvedic naming	Regional Shankhpushpi, Vishnukranta, Shankhavel	Brahmi, Sarasvati, Kapotavanka in API synonyms
Classical context	Relevant through the Shankhpushpi medhya tradition; API official source is C. pluricaulis	API lists Medhya, Rasayana, Matiprada, Vatahara, Kaphahara actions
Notable constituents	Scopoletin, scopolin, umbelliferone, beta-sitosterol, betaine, flavonoids and alkaloids	Bacosides and bacopasides are the best-characterized constituents
Modern evidence profile	Mainly animal, in-vitro, in-silico, and traditional-use literature	Larger published human trial literature for cognition

Classical Medhya Rasayana Context

Charaka’s Rasayana chapter lists four Medhya Rasayana approaches: Mandukaparni juice, Yashtimadhu powder with milk, Guduchi juice with root and flowers, and Shankhapushpi paste. The verse specifically praises Shankhapushpi as intellect-promoting. This classical praise supports the importance of the Shankhpushpi tradition, while the exact botanical source must still be identified carefully in modern writing and clinical use.

In the API monograph for official Shankhapushpi, the listed properties are Katu, Tikta, and Kashaya rasa; Sara guna; Shita virya; Katu vipaka; and actions including Balya, Ayushya, Kaphahara, Medhya, Pittahara, Rasayana, and Mohanashaka. The listed therapeutic uses include Manasaroga and Apasmara, and the powder dose is 3–8 g. Because this monograph is for Convolvulus pluricaulis, it should not be automatically copied onto every Evolvulus alsinoides product without checking the actual botanical source.

Phytochemistry of Evolvulus alsinoides

Evolvulus alsinoides contains several documented phytochemical groups, including coumarins, flavonoids, alkaloids, phytosterols, and other secondary metabolites. Reviews and analytical work list constituents such as scopoletin, scopolin, umbelliferone, beta-sitosterol, betaine, triacontane, and shankpushpine. Scopoletin is a coumarin constituent, not a furanocoumarin, and it should be described as one important marker rather than as the only active principle of the plant.

A 2024 analysis of scopoletin-rich Evolvulus alsinoides extract quantified scopoletin by HPTLC and evaluated antioxidant, in-silico, and zebrafish embryo toxicity parameters. This supports careful standardization: the herb may be valuable, but dose, extract type, and product identity matter.

Modern Pharmacology for Memory and Calm Focus

Animal work with Evolvulus alsinoides has described improved learning and memory performance in rodent paradigms and reversal of scopolamine-induced amnesia. Other preclinical work has described adaptogenic and anti-amnesic activity in stress and memory models. In an intracerebroventricular streptozotocin model, Evolvulus alsinoides was evaluated for cognitive impairment, oxidative stress, cholinergic function, and related neuronal markers.

A comparative mouse study involving Evolvulus alsinoides and Centella asiatica reported neuroprotective and nootropic activity in scopolamine-induced amnesia, with reduced acetylcholinesterase activity in brain homogenate. A separate comparison of different plant sources used as Shankhpushpi found that Convolvulus pluricaulis, Evolvulus alsinoides, and Clitoria ternatea all showed central nervous system activity in experimental models, with activity varying by plant and dose.

Where Shankhavali Fits Beside Brahmi

Brahmi remains the better-known herb because its identity as Bacopa monnieri is widely recognized and it has a larger clinical publication base. Shankhavali is different: it sits at the intersection of the Vishnukranta and Shankhpushpi traditions. For practitioners, its strongest place is not as a replacement for Brahmi, but as a carefully identified regional medhya herb for memory support, worry-linked scattered attention, and nervous-system nourishment within an individualized Ayurvedic plan.

When selecting between the two, the first question should be identity. If the label says Brahmi, the botanical source should be Bacopa monnieri. If the label says Shankhpushpi, the source may be Convolvulus pluricaulis, Evolvulus alsinoides, Clitoria ternatea, or another regional source unless the manufacturer declares the botanical name. If the label says Vishnukranta or Evolvulus alsinoides, it is referring to Shankhavali as discussed here.

Traditional Forms and Practical Use

Because the official API dose applies to Convolvulus pluricaulis Shankhapushpi, while Shankhavali products may use Evolvulus alsinoides, practical dosing should be guided by the product identity and a qualified practitioner. The safest approach is to avoid generic “Shankhpushpi” dosing and confirm the plant on the label before use.

Form	Verified guidance	Best practice
Official Shankhapushpi powder	API dose: 3–8 g powder; official plant is Convolvulus pluricaulis	Use only when the botanical source is clear
Brahmi powder	API dose: 1–3 g powder for Bacopa monnieri	Choose when a clearly identified Brahmi preparation is desired
Evolvulus alsinoides powder or extract	Dose varies by product and extraction method	Follow practitioner guidance and manufacturer standardization
Syrup, ghrita, or compound formula	Ingredients vary widely by manufacturer	Check whether Shankhpushpi means C. pluricaulis, E. alsinoides, or another source

Growing and Identifying Shankhavali

Authentic Evolvulus alsinoides is a small, slender, hairy herb with prostrate or ascending stems. Botanical descriptions record petiolate or subsessile leaves, blue flowers that may rarely be white, and solitary or few-flowered axillary inflorescences. The flowers are small, broadly funnel-shaped, and the plant is widely distributed across tropical and subtropical regions.

For field identification, the blue-flowered, low-growing, hairy habit is helpful but not sufficient. Shankhpushpi commerce includes multiple species, and dried material can be difficult to identify visually. When buying the herb for memory support, the label should state the Latin binomial, the plant part used, and whether it is a powder, decoction base, syrup, ghrita, or standardized extract.

Who May Benefit Most from Shankhavali?

Shankhavali is best considered as a traditional medhya herb for people seeking gentle cognitive and nervous-system support, especially when forgetfulness is accompanied by restlessness, worry, poor sleep rhythm, or mental fatigue. Students, knowledge workers, and older adults may consider it as part of a broader Ayurvedic plan that also includes sleep regularity, digestion support, suitable diet, and reduced overstimulation.

Students with stress-linked forgetfulness and scattered attention
Adults with mental fatigue, excessive rumination, or poor recall under pressure
People seeking a Shankhpushpi-family herb but wanting a clearly identified botanical source
Those who do not tolerate Brahmi well and need a practitioner-guided alternative
Older adults seeking rasayana-style support without replacing medical evaluation for cognitive decline

Safety Note

Important: Do not use Shankhavali, Shankhpushpi, Brahmi, or any medhya herb as a substitute for prescribed treatment for epilepsy, dementia, anxiety disorders, depression, insomnia, or any neurological condition. People taking sedatives, antiepileptic medicines, psychiatric medicines, or multiple long-term medications should consult a qualified Ayurvedic practitioner and healthcare provider before use. Pregnancy, lactation, pediatric use, and chronic illness require individualized guidance.

Actionable tip: If you want to try Shankhavali for memory support, buy only a product that clearly states Evolvulus alsinoides on the label. Begin with practitioner-guided dosing rather than a generic Shankhpushpi dose, take it consistently with a stable sleep routine, and assess changes in focus, recall, sleep, digestion, and mood over several weeks.

References

Vacha (Sweet Flag): The Ayurvedic Brain Tonic Most People Overlook

Dr. Ananya Sharma — Tue, 24 Mar 2026 06:00:00 +0000

Vacha (Acorus calamus L.), also known as sweet flag, is one of Ayurveda’s sharper and more specialized herbs for the head, throat, speech, memory, and Kapha-Vata patterns of heaviness or obstruction. It is not a casual daily tonic like many popular wellness herbs. Classical Ayurveda values it as Medhya and Kanthya, while modern safety data makes careful sourcing, processing, dose, and professional supervision essential.

What Is Vacha? A Botanical and Classical Overview

Vacha is the dried rhizome of Acorus calamus L., a semiaquatic plant traditionally described in the Ayurvedic Pharmacopoeia of India as growing wild or cultivated in India, including Himalayan regions up to about 1800 meters. Modern botanical classification places Acorus calamus in the family Acoraceae, while older Ayurvedic pharmacopoeial descriptions list it under Araceae. The rhizome is aromatic, pungent, and bitter, which matches its strong, penetrating classical use profile.

Classical Ayurvedic Profile

The Ayurvedic Pharmacopoeia of India gives Vacha a clearly warming, sharp, Kapha-clearing, and Vata-pacifying profile. This explains why it is traditionally selected for conditions involving heaviness, dullness, mucus obstruction, impaired clarity, and disorders of the voice, memory, breathing, digestion, and mind.

Ayurvedic Category	Classical Description
Rasa	Katu and Tikta — pungent and bitter
Guna	Laghu and Tikshna — light and sharp
Virya	Ushna — heating
Vipaka	Katu — pungent post-digestive effect
Karma	Dipani, Krimihara, Kanthya, Kaphahara, Medhya, Vatahara, Mala-Mutra Vishodhani, and Vamaka

The Medhya Rasayana Context

Charaka’s well-known group of four Medhya Rasayana herbs consists of Mandukaparni, Yashtimadhu, Guduchi, and Shankhapushpi. Vacha is not one of those four in that classical passage, but the Ayurvedic Pharmacopoeia of India still classifies Vacha as Medhya, meaning supportive of intellect and cognitive function, and Kanthya, meaning beneficial for the throat or voice. Its place in practice is therefore more specific than a general memory tonic: it is especially suited to Kapha-Vata patterns where dullness, heaviness, poor articulation, mucus, or blocked expression are prominent.

Modern Pharmacology: Plausible Mechanisms

Modern work on Acorus calamus is mostly laboratory and animal-based, so it should be understood as mechanistic support rather than proof of self-treatment benefit. Its essential oil and asarone constituents have been evaluated for acetylcholinesterase inhibition, a mechanism relevant to cholinergic signaling. Alpha-asarone has also been studied in rodent seizure models, while other animal work has examined memory, anxiety, oxidative stress, neuroinflammation, neuropathic pain, and ischemic brain injury models.

Traditional Benefits and Use Contexts

Vacha’s traditional value comes from its combination of Medhya, Kanthya, Kaphahara, Vatahara, and Dipani actions. It is a focused herb for practitioners, not a general supplement to add casually to a daily routine.

1. Speech Clarity and Throat Support

Because Vacha is listed as Kanthya and Medhya, it has a classical role in supporting clarity of voice, articulation, and the throat channels when Kapha heaviness or Vata-Kapha disturbance is present. In children, delayed speech, stammering, or unclear articulation should always be assessed by qualified pediatric and speech professionals, and Vacha should be used only under direct supervision from a qualified practitioner.

2. Memory Weakness and Mental Fog

The Ayurvedic Pharmacopoeia of India lists Smriti Daurbalya, or weakness of memory, among Vacha’s therapeutic uses. Its sharp, heating, light qualities make it especially relevant where the practitioner identifies Kapha-type heaviness, sluggishness, or dullness rather than dryness, depletion, or excess heat. In traditional practice, it is commonly considered alongside broader measures for digestion, sleep, daily routine, and other Medhya herbs.

3. Apasmara and Seizure-Adjacent Classical Context

Vacha is listed in the Ayurvedic Pharmacopoeia of India for Apasmara, a classical condition often discussed in relation to seizure-like presentations and altered consciousness. This does not make Vacha a substitute for antiepileptic medication. Anyone with epilepsy, a seizure disorder, fainting episodes, or neurological disease should use it only with approval from the treating neurologist and a qualified Ayurvedic physician.

4. Kapha-Type Mental Dullness and Lethargy

Vacha’s Kaphahara, Dipani, Tikshna, and Ushna qualities make it traditionally suitable when mental dullness is associated with heaviness, low digestive fire, excess sleepiness, sluggish expression, or mucus dominance. It is not appropriate for every person with low mood, fatigue, anxiety, or cognitive change; the constitution, strength, digestion, heat signs, medications, and medical history must guide its use.

5. Respiratory and Digestive Kapha Patterns

The Ayurvedic Pharmacopoeia of India lists Vacha for Svasa, Kasa, Vibandha, and Adhmana, linking it with traditional respiratory and digestive uses. Its pungent-bitter taste, heating potency, and Kapha-reducing action make it a strong herb for clearing heaviness and stimulating movement, but its intensity also explains why dose and duration must remain conservative.

Dosage and Forms

The Ayurvedic Pharmacopoeia of India gives the dose of Vacha powder as 60–120 mg and notes that Vacha should undergo Shodhana before internal use. A much higher powder dose of 1–2 g is listed only for inducing therapeutic emesis and should be understood as a physician-directed classical procedure, not a home dosage.

Use Context	Form	Classical or Practical Guidance
Internal classical use	Purified rhizome powder	60–120 mg, only when properly processed and professionally indicated
Therapeutic emesis	Powder	1–2 g only in a physician-directed Vamana context
Children’s speech or cognitive support	Practitioner-selected preparation	No casual home dose; use only under direct professional supervision
Classical compound formulations	Churna, arishta, vati, or taila as applicable	Follow the specific formulation label and clinician’s instructions

Safety: Beta-Asarone, Cytotype, and Legal Restrictions

Vacha requires unusual caution because some Acorus calamus varieties contain beta-asarone. European safety review material describes beta-asarone as carcinogenic in rodents and potentially genotoxic, and United States federal regulations state that food containing added calamus, calamus oil, or calamus extract is deemed adulterated. These restrictions are especially relevant to internal use of essential oil or untested extracts.

Different cytotypes of Acorus calamus vary greatly in beta-asarone content. The diploid form has been described as virtually free of beta-asarone, while triploid and tetraploid forms may contain substantially higher levels, with the tetraploid Indian form described as especially high. For this reason, responsible use depends on correct botanical identity, cytotype or origin awareness, purification status, and beta-asarone testing where available.

Vacha is a classical medicine, not a casual wellness spice: its dose, processing status, botanical identity, and beta-asarone profile matter.

Practical safety guidance:

Use Vacha only under the guidance of a qualified Ayurvedic physician or qualified healthcare provider.
Do not take calamus essential oil internally.
Avoid unsupervised use during pregnancy, lactation, childhood, epilepsy, liver disease, or neurological illness.
Discuss use with a clinician if taking antiepileptic, sedative, psychiatric, liver-metabolized, or neurological medications.
Prefer products with clear botanical identity, GMP manufacturing, purification status, and beta-asarone testing.
Avoid long-term daily self-use.

Disclaimer: This article is for educational purposes only and does not constitute medical advice. Vacha is a potent herb with significant safety considerations. Consult a qualified Ayurvedic practitioner and an appropriate healthcare provider before using it, especially for children, pregnancy, lactation, epilepsy, liver disease, neurological conditions, or prescription medication use.

Classical Formulations Containing Vacha

The Ayurvedic Pharmacopoeia of India lists several important formulations associated with Vacha. These compound preparations reflect the traditional preference for using Vacha in carefully balanced combinations rather than as a casual single-herb supplement.

Vachadi Taila: A medicated oil preparation listed among important Vacha formulations.
Vacha Lasunadi Taila: A classical oil preparation that includes Vacha in combination with other ingredients.
Sarasvata Churna: A classical powder preparation associated with Vacha and traditionally used in cognitive and speech-related contexts.
Sarasvatarishta: A fermented classical preparation listed among important formulations for Vacha.
Manasamitra Vataka: A classical tablet formulation listed in the Vacha monograph.
Chandraprabha Vati: A well-known classical tablet formulation included in the pharmacopoeial list for Vacha.
Khadiradi Vati: A classical lozenge/tablet preparation listed among important formulations.
Hinguvachadi Churna: A classical powder formulation that includes Vacha in a digestive and Vata-Kapha context.

How Vacha Fits Into a Complete Neurological Protocol

In a responsible Ayurvedic plan, Vacha is not treated as a stand-alone cure. A practitioner first considers Agni, bowel function, sleep, stress, speech development, neurological diagnosis, medication use, strength, age, pregnancy status, and signs of excess heat or depletion. When Vacha is appropriate, it is usually a small, processed, time-limited part of a broader plan that may include diet, routine, breathing practices, speech or neurological rehabilitation, and other carefully selected herbs.

Vacha remains one of Ayurveda’s most distinctive herbs for speech, throat clarity, memory weakness, Kapha heaviness, and Vata-Kapha neurological patterns. Its value is real within its traditional context, but its safety profile demands respect. Used casually, it is the wrong herb; used with proper processing, dose, sourcing, and supervision, it remains an important medicine in the Ayurvedic materia medica.

References

Shankhpushpi for Anxiety: The Nootropic Herb Psychiatry Should Study

Dr. Meera Iyer — Fri, 06 Mar 2026 20:03:18 +0000

In a 2014 mouse elevated-plus-maze study, an ethanolic extract of Convolvulus pluricaulis given orally at 500 mg/kg produced a mean open-arm time of 84.0 ± 12.5 seconds, compared with 23.4 ± 5.3 seconds in untreated controls. Diazepam at 1 mg/kg produced 156.6 ± 32.8 seconds. These results support an anxiolytic-like effect in one animal model, but they do not show that the extract has “54% of diazepam’s potency.” Potency cannot be calculated by directly comparing one behavioural endpoint at dissimilar doses, and the experiment did not establish clinical efficacy in people.

This captures the present state of Shankhpushpi research: a credible preclinical signal and a modern pharmacopoeial identity, but major uncertainty about species, extract composition, mechanism, human dosing, interactions, and effectiveness for diagnosed anxiety disorders.

The Identity Problem: Which Plant Is Shankhpushpi?

The first research question is botanical, not pharmacological. “Shankhpushpi” has been applied to more than one plant in Indian practice and commerce. A comparative pharmacognostic investigation published in 2010 documented four plants traditionally traded or used under the name:

Convolvulus pluricaulis Choisy (Convolvulaceae)
Evolvulus alsinoides L. (Convolvulaceae)
Clitoria ternatea L. (Fabaceae)
Canscora decussata (Roxb.) Schult. (Gentianaceae)

These names are not interchangeable experimental labels. The 2010 study compared morphology, microscopy, physicochemical constants, and chromatographic fingerprints to support authentication. A paper or product that says only “Shankhpushpi” may therefore be impossible to reproduce reliably.

The Ayurvedic Pharmacopoeia of India, Part I, Volume II, defines Shankhapushpi as the dried whole plant of Convolvulus pluricaulis Choisy. Its monograph describes a prostrate or sub-erect, spreading, hairy perennial herb with a woody rootstock. The same monograph notes that Clitoria ternatea and Evolvulus alsinoides are used as Shankhapushpi in certain parts of India. Thus, the pharmacopoeia supplies a reference identity while also acknowledging regional substitution.

A 2016 study developed an internal-transcribed-spacer multiplex PCR assay to distinguish Convolvulus prostratus—the name used by those authors for the plant also cited as C. pluricaulis—from E. alsinoides. It generated species-specific products of 200 and 596 base pairs and detected 10% admixture. Molecular testing is useful, but trials still need documented sourcing, voucher specimens, and chemical standardization.

Classical and Pharmacopoeial Profile

In the Charaka Samhita tradition, Shankhapushpi is grouped with Mandukaparni, Yashtimadhu, and Guduchi in medhya rasayana practice. “Medhya” concerns intellect, memory, and mental faculties within Ayurveda; it is not automatically a claim to treat generalized anxiety disorder, dementia, or another modern diagnosis.

The official pharmacopoeial monograph gives the following attributes for Convolvulus pluricaulis. These are the API entries and should not be replaced with properties copied from a different regional substitute or later secondary source:

Ayurvedic category	API description
Rasa	Tikta, Katu, Kashaya
Guna	Snigdha, Pichchila
Virya	Shita
Vipaka	Madhura
Karma	Tridoshahara, Rasayana, Medhya, Balya, Mohanashaka, Ayushya

The API lists manasaroga and apasmara among therapeutic uses and gives 3–8 g of powder as the monograph dose. These categories are not exact synonyms for contemporary anxiety disorders or epilepsy and require qualified clinical interpretation.

What the Anxiety Studies Actually Show

The evidence most often cited for anxiety consists mainly of rodent experiments. These studies can identify a behavioural signal and guide mechanism research, but they cannot determine whether an authenticated product is effective, safe, or appropriately dosed for a person with an anxiety disorder.

Study	Material and design	Verified finding	Main limitation
Nahata and colleagues, 2009	Rodent experiments using ethyl-acetate fractions of E. alsinoides and C. pluricaulis	Both materials produced anxiolytic-like effects in behavioural tests	Animal data from selected fractions; not a human trial
Malik and colleagues, 2011	Extracts from three commonly used botanical sources of Shankhpushpi	Nootropic, anxiolytic-like, and CNS-depressant activities varied by plant source and dose	Source-dependent results prevent a single conclusion for every “Shankhpushpi” product
Siddiqui and colleagues, 2014	Mice given aqueous, ethanolic, or chloroform extracts of C. pluricaulis at 500 mg/kg	All three extracts increased open-arm time; ethanolic extract reached 84.0 seconds versus 23.4 seconds in controls	Single acute animal experiment with a high extract dose
Heba and colleagues, 2017	Mouse model of ethanol intake and withdrawal	Shankhpushpi reduced withdrawal-associated anxiety-like behaviour and altered cortico-hippocampal GABA findings	A model of alcohol withdrawal, not ordinary clinical anxiety

Open-arm time is a behavioural proxy, not a direct measure of calmness, receptor occupancy, or therapeutic equivalence. The extract also lacked a quantified marker specification. Because different botanical sources produce different CNS profiles, future trials should report the Latin binomial, plant part, solvent, extraction ratio, voucher specimen, contaminant testing, fingerprint, and marker range.

GABAergic Activity: A Plausible Pathway, Not a Settled Human Mechanism

The 2014 paper proposed possible involvement of the GABA-benzodiazepine system, but it did not measure receptor binding, chloride flux, or human GABA-A activity. Claims of proved benzodiazepine-site agonism or benefit without tolerance go beyond its evidence.

The 2017 ethanol-withdrawal experiment provides more specific preclinical support. In that mouse model, the anti-anxiety-like effect was blocked by a GABA-A antagonist, and chronic administration was associated with increased cortico-hippocampal GABA. This supports GABA-A involvement under the conditions of that experiment. It does not establish GABA-A as the sole mechanism of every preparation or predict the size of an effect in human anxiety.

Reviews report alkaloids, coumarins, flavonoids, and phytosterols in C. pluricaulis, including shankhpushpine, convolamine, scopoletin, kaempferol, and beta-sitosterol. Presence does not establish mechanism, and content varies with identity and extraction. The API gives only the broad constituent entry “alkaloid,” not a clinical standard for anxiety.

Mechanistic caution: A 2022 network-pharmacology paper predicted multiple targets and pathways relevant mainly to dementia research. Computational target mapping is hypothesis-generating. It cannot confirm that a compound reaches the human brain at an active concentration, binds the predicted target in vivo, or improves a clinical outcome.

Cognition and Memory: Promising Preclinical Data, Limited Clinical Proof

The cognition literature remains dominated by laboratory models. Rodent studies report effects after scopolamine- or aluminium-associated impairment. In one aluminium-neurotoxicity model, C. pluricaulis affected muscarinic M1 receptor, choline acetyltransferase, and NGF-TrkA expression. These findings do not establish prevention or treatment of human dementia.

Another rodent study used piracetam as a reference in learning and memory tests. A reference group does not establish clinical equivalence, and animal performance cannot be turned into a prescribing comparison.

Human evidence is modest. A 2015 comparative study enrolled 102 healthy young volunteers and evaluated four 500 mg Shankhapushpi tablets twice daily after food with milk for two months against a programme involving yoga and Satvavajaya Chikitsa. Some memory measures improved, but the herbal intervention was not tested against an inert placebo under a fully blinded design, and the participants did not have anxiety disorders or dementia. The study therefore offers preliminary information about cognitive testing, not proof of treatment for a psychiatric or neurodegenerative condition.

An Alzheimer’s Drug Discovery Foundation evidence review likewise concluded that well-controlled human data are lacking. Comparative trials have not established superior safety or efficacy over prescription drugs.

Dose and Preparation: What Can Be Stated Reliably

Mouse doses should not be converted into self-treatment doses by simple body-surface-area arithmetic. Such calculations do not account for extract ratio, constituent exposure, metabolism, product quality, or indication.

Preparation or context	Verified amount	How to interpret it
API whole-plant powder	3–8 g	Pharmacopoeial monograph dose for the authenticated crude drug; not evidence of efficacy for generalized anxiety disorder
Tablet used in the 2015 volunteer study	Four 500 mg tablets twice daily for 60 days	A study-specific regimen in healthy young adults; not a universal clinical dose
Commercial syrups, capsules, and extracts	No single evidence-based equivalent dose	Concentration, species, plant part, extraction ratio, sugar content, and marker compounds may differ

A useful label states the botanical name, plant part, crude-drug equivalent, solvent and ratio, and batch testing. “Shankhpushpi 500 mg” is incomplete when products may contain powder, concentrated extract, or another species.

Safety and Herb–Drug Interactions

Human safety information is insufficient for confident claims about long-term use or combinations with psychiatric and neurological medicines. Traditional use cannot replace adverse-event monitoring and interaction studies.

Phenytoin: A 1992 report described two patients who lost seizure control while using a Shankhapushpi preparation with phenytoin. Repeated administration in rats reduced phenytoin concentration and anticonvulsant activity. Although botanical authentication was inadequate by current standards, patients should not combine them without the prescribing clinician.
Benzodiazepines, sedating antihistamines, alcohol, and other CNS depressants: Some extracts show CNS-depressant or sleep-potentiating activity in animals. Additive drowsiness is a reasonable precaution, although human risk is unquantified.
Antihypertensive treatment: Limited summaries note possible blood-pressure-lowering effects. A person with low blood pressure or prescribed antihypertensives should seek clinical advice and monitoring rather than assuming the combination is harmless.
SSRIs, SNRIs, and other antidepressants: Computational literature does not establish a clinical serotonin-syndrome interaction. Combination safety is inadequately studied.
Pregnancy, breastfeeding, children, liver or kidney disease: Adequate controlled safety data are lacking. Unsupervised medicinal use should be avoided in these groups unless an appropriately qualified clinician has assessed the individual situation.

Safety advice: Do not stop or replace prescribed anxiety, seizure, sleep, or blood-pressure treatment with Shankhpushpi. Discuss the exact product with the prescribing healthcare provider and a qualified Ayurvedic practitioner, especially when symptoms are severe or medicines are already used.

Research Gaps That Should Shape the Next Trial

The evidence does not show that Shankhpushpi “works like a benzodiazepine.” It shows that authenticated C. pluricaulis deserves better-designed human research addressing the following gaps.

Diagnosed anxiety populations: PubMed-indexed literature does not provide an adequately powered, double-blind, placebo-controlled trial of authenticated C. pluricaulis for a defined anxiety disorder.
Botanical authentication: Trials need a voucher specimen and molecular or validated pharmacognostic confirmation, not only the common name Shankhpushpi.
Chemical standardization: Extract ratio, solvent, fingerprint, marker range, contaminants, pesticides, microbes, and heavy metals should be reported batch by batch.
Pharmacokinetics: Human absorption, active metabolites, brain exposure, half-life, and dose proportionality have not been established for a clinically standardized preparation.
Safety and interactions: Studies should prospectively monitor sedation, cognition, blood pressure, liver and kidney indices, withdrawal effects, and interactions with commonly prescribed medicines.
Clinically meaningful outcomes: A future trial should use a preregistered primary anxiety scale, functional outcomes, adverse-event reporting, and follow-up after discontinuation rather than relying only on laboratory memory tests or subjective impressions.

Where the Evidence Leaves Us

Shankhpushpi has a genuine Ayurvedic context, an API monograph for Convolvulus pluricaulis, and anxiolytic-like and cognitive signals in animal models. That justifies investigation, not a percentage comparison with diazepam, confirmed GABA-A agonism in people, or replacement of evidence-based anxiety care.

A defensible next step is a preregistered, randomized, double-blind, placebo-controlled study using authenticated, chemically characterized C. pluricaulis, preceded by dose-finding and safety work. Until then, species verification, professional supervision, medication review, and honest uncertainty are more appropriate than promotional certainty.

References

Nothing in this article diagnoses or treats a medical condition. Use it as educational information and consult a qualified Ayurvedic practitioner or physician before starting herbs, supplements, detoxes, or therapeutic protocols, especially if pregnant, managing a condition, or taking medication.

Centella Asiatica vs Bacopa: Two Brain Herbs Confused by Everyone

Dr. Meera Iyer — Fri, 06 Mar 2026 20:03:15 +0000

In Indian herbal commerce, the name Brahmi may be used for either Bacopa monnieri or Centella asiatica. The two plants are not botanically interchangeable, even though both have been associated with memory, intellect, and mental well-being. This overlap in common names can cause consumers to purchase a different plant from the one used in a clinical trial or described in a particular monograph.

Official Indian pharmacopoeial nomenclature separates them clearly. The Ayurvedic Pharmacopoeia of India identifies Brahmi as Bacopa monnieri and Mandukaparni as Centella asiatica. Product labels, therefore, should state the complete botanical name rather than relying on “Brahmi” alone.

The distinction matters because the plants belong to different botanical families, contain different characteristic compounds, and have not been investigated equally for the same clinical purposes.

The Naming Problem: One Common Name, Two Botanical Species

Bacopa monnieri and Centella asiatica have both circulated under the name Brahmi in regional practice, trade, popular literature, and supplement marketing. Reviews of their nomenclature have specifically noted that this shared name can lead to substitution or uncertainty about the botanical identity of commercial products.

In the Ayurvedic Pharmacopoeia of India, the identities are unambiguous: Brahmi is Bacopa monnieri, while Mandukaparni is Centella asiatica. These pharmacopoeial identities provide a practical standard for manufacturing, prescribing, purchasing, and discussing the two herbs.

The frequently cited Medhya Rasayana passage in the Charaka Samhita should also be described accurately. In Chikitsa Sthana 1.3.30–31, the four intellect-supporting preparations are Mandukaparni juice, Yashtimadhu powder taken with milk, Guduchi juice, and Shankhapushpi paste. The passage names Mandukaparni, not a four-herb group containing both Brahmi and Mandukaparni.

This does not make the two plants interchangeable. A classical therapeutic category such as Medhya can include more than one substance, while each substance retains its own botanical identity, preparation, dose, and clinical context.

How to Tell the Plants Apart

The plants are readily distinguishable when their leaves and growth habits are examined. Botanical identification is more dependable than a vernacular name printed on a packet or repeated by a retailer.

Centella asiatica (Mandukaparni) is a creeping herb with rounded, kidney-shaped, or broadly fan-shaped leaves borne on conspicuous petioles. The margins are usually crenate or scalloped. Its small flowers occur in compact umbels close to the nodes. It commonly grows in moist ground, marshy places, and other wet habitats.

Bacopa monnieri (Brahmi) is also a low, creeping herb, but its leaves are small, opposite, thick, succulent, and nearly sessile. They are generally oblong, obovate, or spatulate rather than rounded and fan-shaped. The flowers are solitary and typically white to pale blue or violet.

A useful field distinction is therefore straightforward: a rounded leaf on a long stalk suggests Centella, while a small, fleshy, nearly stalkless leaf arranged opposite another leaf suggests Bacopa.

Neither plant is confined to a single part of India. Bacopa monnieri occurs widely in tropical and subtropical wet habitats, while Centella asiatica has an extensive Old World distribution extending from parts of Africa and Asia to Australia and the western Pacific. Commercial origin alone cannot establish identity.

Different Chemistry and Different Extracts

The characteristic phytochemical profiles of the two plants are distinct. This is one reason that milligram amounts cannot be compared directly and one species should not be substituted for the other in a formula or clinical protocol.

Centella Triterpenes

The best-known constituents of Centella asiatica include the pentacyclic triterpenes asiaticoside, madecassoside, asiatic acid, and madecassic acid. The proportions vary with the plant material, geographical source, processing method, and type of extract.

Centella preparations used in experiments and clinical studies have included whole-herb products, hydroalcoholic extracts, and defined triterpenic fractions. These preparations are not automatically equivalent. A product standardized to total triterpenes may differ substantially from one standardized to a particular percentage of asiaticoside or madecassoside.

Laboratory investigations have examined effects involving extracellular-matrix formation, inflammatory signalling, oxidative stress, vascular function, and nervous-system pathways. Such mechanistic findings help explain why Centella has been studied in skin, wound, and venous conditions, but they do not establish that every oral or topical Centella product will produce the same clinical result.

Bacopa Saponins

Bacopa monnieri contains a complex group of dammarane-type triterpenoid saponins commonly described as bacosides and bacopasides. “Bacoside A” is not one isolated molecule; it is a mixture that includes bacoside A3, bacopaside II, bacopasaponin C, and a jujubogenin-related saponin.

The historical term “bacoside B” has not always been used consistently, so a label stating only “bacosides” does not fully describe an extract. Analytical results can also differ according to whether ultraviolet spectrophotometry, high-performance liquid chromatography, or another method was used. Percentages obtained by different assays should not be treated as directly interchangeable.

Preclinical work has examined Bacopa in relation to cholinergic and monoaminergic signalling, antioxidant defence, synaptic activity, and memory-related brain processes. Human conclusions, however, should be based on controlled clinical outcomes rather than extrapolated from cellular or animal mechanisms alone.

What the Human Cognitive Trials Indicate

The human cognitive literature is more substantial for Bacopa monnieri than for Centella asiatica, although the magnitude and consistency of Bacopa’s effects vary by study, extract, population, outcome measure, and duration.

A 2014 meta-analysis identified nine randomized, placebo-controlled Bacopa trials involving 518 participants. Data suitable for quantitative analysis represented 437 participants. The pooled findings favoured Bacopa for certain measures of attention-related processing speed, including choice reaction time and Trail Making Test Part B, but the authors also called for larger, well-designed comparative trials.

One frequently cited randomized trial enrolled 46 healthy adults and compared 300 mg daily of a standardized Bacopa monnieri extract with placebo. Assessments were conducted at baseline, five weeks, and twelve weeks. At twelve weeks, the Bacopa group had improvements in several measures, including visual information processing, learning rate, memory consolidation, and state anxiety. The delayed pattern is consistent with Bacopa being investigated as a regularly administered herb rather than an immediate stimulant.

A separate systematic review of randomized trials found the most consistent signal in memory free-recall tasks. Results for many other cognitive domains were absent, inconsistent, or measured too differently for a broad conclusion. It is therefore more accurate to describe Bacopa as having promising evidence for selected memory and attention outcomes than as a universally proven cognitive enhancer.

Many adult trials have used approximately 300 mg per day of a standardized extract for about twelve weeks, but that number is not a universal Ayurvedic or pharmacological dose. Extract concentration, plant part, analytical method, formulation, health status, and concomitant medicines all affect whether two products are comparable.

Centella and Cognitive Outcomes

Human cognitive studies of Centella asiatica are fewer and generally smaller. A study involving 28 healthy older adults evaluated daily doses of 250, 500, or 750 mg for two months. Some measures of working memory and mood changed during the study, particularly at the higher dose, but the small sample and multiple dose groups limit the certainty and generalizability of the result.

A later systematic review and meta-analysis did not provide strong support for broad cognitive improvement with Centella. The available trials differed in participants, preparations, doses, treatment periods, and cognitive tests. Some findings relating to alertness or mood were of interest, but Centella cannot be considered clinically equivalent to Bacopa on the basis of the current cognitive literature.

Mandukaparni nevertheless has an authentic place in Ayurveda as one of the substances used in the Medhya Rasayana context. That classical use should be presented on its own terms rather than supported with exaggerated or substituted modern trial claims.

Centella in Wound and Venous Research

Centella asiatica and its triterpenic preparations have also been investigated for wound healing, scar-related applications, and chronic venous insufficiency. This area of study is more characteristic of Centella than of Bacopa, but the findings still require careful interpretation.

A systematic review of Centella in wound healing concluded that it might assist aspects of healing, including angiogenesis, but the included studies used varied preparations, models, wound types, and outcome measures. This heterogeneity prevents all Centella creams, extracts, and triterpene fractions from being treated as equivalent.

A systematic review of oral Centella preparations for chronic venous insufficiency found possible improvements in certain symptoms and physiological measurements. The authors advised caution because of limitations in study quality and reporting. Centella products should not replace wound assessment, infection treatment, compression therapy, vascular evaluation, or other indicated medical care.

Head-to-Head Comparison

The following comparison separates verified botanical identity from areas that remain dependent on the particular preparation and quality of the clinical evidence.

Parameter	Centella asiatica	Bacopa monnieri
Ayurvedic Pharmacopoeia name	Mandukaparni	Brahmi
Botanical family	Apiaceae	Plantaginaceae
Growth form	Creeping herb with rounded leaves on distinct petioles	Creeping succulent herb with small, opposite, nearly sessile leaves
Characteristic constituents	Asiaticoside, madecassoside, asiatic acid, and madecassic acid	Bacosides, bacopasides, and related dammarane-type saponins
Classical point	Mandukaparni is included in Charaka’s four Medhya Rasayana preparations	Recognized as Brahmi in the Ayurvedic Pharmacopoeia of India
Human cognitive literature	Limited, small, and methodologically varied	Multiple randomized trials and systematic reviews, with the clearest findings in selected memory and attention measures
Other studied areas	Wound healing, scar-related preparations, and chronic venous insufficiency	Memory performance, attention-related processing, and learning measures
Common preparation problem	Total-triterpene and single-marker extracts may differ	“Bacoside” percentages may differ according to extract and assay method
Common adverse effects	Topical irritation or allergy; mild digestive or other nonspecific effects may occur	Nausea, abdominal cramping, and increased stool frequency are among the more commonly reported effects
Important caution	Rare cases of clinically apparent liver injury have been reported	Possible cholinergic, thyroid-related, and drug-metabolism interactions require clinical consideration

Matching the Plant to the Intended Use

For a person comparing products with published human memory trials, Bacopa monnieri is the more directly studied species. This does not guarantee benefit, and it does not mean that every Bacopa powder or capsule matches the extracts used in the trials. The botanical name, extract specification, dose, and treatment duration must all be considered.

For a person considering a Centella preparation for a scar, wound, swelling, or venous symptoms, the exact formulation and clinical diagnosis are important. An oral extract used in a venous-insufficiency trial is not equivalent to a cosmetic cream, and neither should be used to self-manage an infected wound, a non-healing ulcer, sudden leg swelling, or suspected vascular disease.

Ayurvedic prescribing also involves more than matching one herb to one symptom. A qualified practitioner considers the verified drug identity, formulation, processing, route of administration, digestive tolerance, accompanying substances, individual constitution, disease stage, and other treatments already being used.

What to Check on the Label

A trustworthy label should allow the purchaser and practitioner to determine exactly which plant and preparation are present. A common name without botanical details is inadequate for comparing the product with either pharmacopoeial standards or clinical trials.

Complete Latin name: The label should state either Bacopa monnieri or Centella asiatica. “Brahmi” alone does not establish the species.
Plant part: Look for a declaration of the whole plant, aerial parts, leaves, or other material actually used.
Preparation type: Distinguish whole-herb powder from an extract. For an extract, check the extraction ratio, solvent where disclosed, and quantity equivalent to the starting herb.
Marker compounds and assay method: A bacoside or triterpene percentage is more useful when the analytical method is also identified. Percentages generated by different methods may not be comparable.
Batch and manufacturer details: Check the batch number, expiry date, storage instructions, manufacturer, and applicable regulatory information.
Independent quality verification: Certifications such as USP Verified or appropriate NSF certification can provide information about identity, declared ingredients, contaminants, and manufacturing quality. They do not prove that a supplement will be effective for a particular condition.

In the United States, dietary supplements are not approved by the Food and Drug Administration for safety and effectiveness before they are marketed in the same manner as medicines. This makes accurate identity, responsible manufacturing, transparent testing, and professional guidance especially important.

Safety and Interactions

Bacopa monnieri commonly causes gastrointestinal effects such as nausea, abdominal cramping, or increased stool frequency in some users. Because Bacopa may have cholinergic activity and may affect thyroid-related or drug-metabolizing pathways, people using prescription medicines should obtain professional advice before taking a concentrated extract.

Centella asiatica can cause topical irritation or allergic contact reactions. Oral use has generally been associated with mild and nonspecific adverse effects, but rare cases of clinically apparent liver injury have been reported. A person who develops jaundice, dark urine, marked itching, persistent nausea, or unusual fatigue after starting an herbal product should stop it and seek medical assessment.

Pregnancy, breastfeeding, childhood, liver disease, thyroid disorders, cardiovascular conditions, planned surgery, and concurrent medication use require individualized guidance. The safety of a culinary or traditional preparation should not automatically be applied to a concentrated standardized extract.

The Practical Conclusion

Brahmi and Mandukaparni should not be presented as two names for one botanical drug. Under the Ayurvedic Pharmacopoeia of India, Brahmi is Bacopa monnieri and Mandukaparni is Centella asiatica. Both have associations with intellect-supporting use, but Charaka’s specific four-item Medhya Rasayana passage names Mandukaparni together with Yashtimadhu, Guduchi, and Shankhapushpi.

For modern product selection, the Latin binomial is the starting point. The plant part, extract type, marker compounds, analytical method, dose, and duration determine whether a supplement resembles the preparation described in a pharmacopoeia or clinical trial. Reading “Brahmi” on the front of a bottle is not enough.

This article is for educational purposes and does not constitute medical advice. Consult a qualified Ayurvedic practitioner or healthcare provider before using either herb, particularly during pregnancy or breastfeeding, for a child, alongside prescription medicines, or when managing a diagnosed health condition.